AZN : IMFINZI Regimen Reduces Death Risk By 25% In Late-Stage Muscle-Invasive Bladder Cancer Trial
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – AstraZeneca Plc (AZN.L, AZN) announced that the NIAGARA Phase III trial showed its IMFINZI (durvalumab) in combination with chemotherapy led to a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and t
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1500340373-9a9166e04b064f1d926066341a5e27f8.jpg "Next Fed Meeting: When It Is In September and What To Expect")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1371757399-3329dac503a74576a455122fc2b08246.jpg "<div>9 Major Medicare Changes for 2025 and How They'll Impact Your Coverage</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1064987572-1a79077cb179458dbbcecc5ac1b660df.jpg "Average Equity In U.S. Homes: Overview, FAQs")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-769720227_2400a-31d6e8ea286f4dea9c854eaf18af463c.jpg "Planning for Retirement? Start With These 5 Steps")